Continued EGFR-TKI with concurrent radiotherapy to improve time to progression (TTP) in patients with locally progressive non-small cell lung cancer (NSCLC) after front-line EGFR-TKI treatment
Clinical and Translational Oncology Aug 12, 2017
Wang Y, et al. – The feasibility of continued epidermal growth factor receptor–tyrosine kinase inhibitor (EGFR–TKI) with concurrent radiotherapy (CTCRT) was gauged in patients with local progression after front–line EGFR–TKI treatment. For this group of patients even with local failure from front–line EGFR–TKI treatment, the treatment modality of CTCRT was considerable and effective.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
